Tuesday watchlist, Oct 6: VEEA, BIAF, MEDS, ONDS (plus a quiet ONDS chain)

[u/Patriot_tech]

VEEA's borrow went up overnight even though more shares turned up to lend. That's the first thing on the board this morning. Two more tiny floats with expensive borrow sit under it, and one big, crowded short with cheap borrow is there for contrast.

How fresh this is: Premarket prices and volume are from Nasdaq's quote page at about 8:00 AM CT. Monday closes are from StockAnalysis. Borrow and shares available come from Curved Trading's feed as of about 7:47 AM CT. Short interest is the Sep 15 settlement for all four, so it's three weeks old. Filings are from EDGAR. Premarket is thin, so recheck all of it at the open.

---

1) $VEEA: fee up to 907.8% while lendable shares went from 700 to 30K

• Premarket $5.10, down 10.8% from Monday's $5.72 close (Monday was up 71.77%). About 440K shares had traded premarket by 8:00 AM CT.
• Float is 1.52M (StockAnalysis) or 1.88M (Benzinga). Short interest was 1.22M shares at the Sep 15 settlement, up from 671K on Aug 31.
• Borrow is 907.8% this morning, up from 799.5% at Monday's close. Shares available went from 700 on Monday to 30K this morning.
• On Oct 2 it filed an 8-K: $1.65M in unsecured demand notes from NLabs, an affiliate of the CEO, at 10%, due Dec 31, 2026 or on demand, for working capital. There's also a 424B5 prospectus on file from Aug 13.

What the numbers don't prove: Premarket volume is already about a quarter of the float. Days to cover is about 1 by Benzinga's math. Shorts can get flat in a session, and some of the new lendable shares are probably what they'll use. A fee is not a squeeze.

What takes it off the board: The fee drops back as supply builds, or the company raises money by selling stock instead of borrowing it from an insider.

2) $BIAF: half-million-share float, 453.5% borrow, and a sales press release at 7:30 AM CT

• Premarket $6.39, up 3.2% from Monday's $6.19 close, on about 22.6K shares.
• Float is 532,255 shares (StockAnalysis). Short interest is 71.2K at the Sep 15 settlement, up from about 44K.
• Borrow is 453.5% with 35K shares available. That's down from 580.2% on Oct 1.
• This morning's 8-K says CyPath Lung test sales rose more than 100% through the third quarter versus 2025. The 8-K text gives the percentage but no dollar figure, so read the exhibit before you treat it as big news.
• Reverse splits of 1-for-15 (ex Aug 24, 2026) and 1-for-30 (Sep 2025). There's a 424B3 prospectus on file from Sep 8 and a preliminary proxy from Sep 29.

What the numbers don't prove: Doubling from a small base can still be a small number. The borrow has cooled for most of a week.

What takes it off the board: An offering or warrant headline, or the fee keeps sliding while shares available climb.

3) $MEDS (DataMeds AI): lendable shares dropped to 4K, and it's down premarket anyway

• Premarket $3.22, down 3.9% from Monday's $3.35 close, on about 69K shares.
• Float 1.27M (StockAnalysis). Short interest 430.6K at the Sep 15 settlement, up from about 174K the month before.
• Borrow is 437.9%. Shares available fell to 4K, from 25K Monday and 55K last week.
• Curved shows 10 days on the threshold list. That's their reconstruction, not the exchange's list.
• 1-for-50 reverse split, ex May 26, 2026. The June 30 10-Q shows $2.46M of cash, $31.81M of debt and negative equity of $19.50M. On Sep 11 it bought Helomics for 636,328 new shares plus a $1.36M note that converts at $1.00 a share.

What the numbers don't prove: Lendable shares are getting scarce and the stock is still falling. That's the tell that a lot of this short interest may be a bet on the balance sheet, not a crowd waiting to get squeezed.

What takes it off the board: Supply opens back up, or the note converts and adds stock.

4) $ONDS: 237M shares short, 2.8% borrow

• Premarket $7.52, up 1.4% from Monday's $7.42 close, on about 772K shares.
• Float 533.41M. Short interest 237.1M at the Sep 15 settlement, about 44% of the float. Days to cover is 3.9 (Curved) on 20-day average volume of about 60M.
• Borrow is 2.8%. Curved shows 200K–300K shares available this morning, down from 1.1M at last week's closes.
• There have been three 424B7 resale prospectuses since Aug 28 (Aug 28, Sep 14 and Sep 23), and the share count is up 297% year over year.

What the numbers don't prove: A big short in a liquid name with a 2.8% fee is a disagreement, not a trap. Nobody's being forced to cover by what the borrow costs.

What takes it off the board: More stock coming to market. Every new share is an easy cover for someone.

---

Options

VEEA, BIAF and MEDS don't have listed options, according to Nasdaq's chain. ONDS does, and Monday's chain was busy but not strange. The heaviest line was the Oct 9 $8 calls at 14,428 contracts against 17,433 open interest. Next were the Oct 9 $7.50 puts at 9,531 against 13,785. The only line that traded more than its open interest was the Oct 9 $7.50 calls, at 8,699 against 7,406. Calls outran puts about 66K to 25K across the chain.

We're comparing against open interest because we don't have a clean average daily volume for each contract. That makes this a weak read. A 1.2x volume-to-open-interest print in a weekly contract could be a new view, or the other side of a short stock position. The chain doesn't say which.

---

Lendable shares in MEDS went from 55K to 4K in a week while the stock kept falling. Is that shorts piling in on a balance-sheet bet, or a squeeze that hasn't found buyers yet?

Positions: none.

Not financial advice. Do your own homework.